Search

Your search keyword '"Fuller, Alice"' showing total 78 results
Start Over Author "Fuller, Alice"
78 results on '"Fuller, Alice"'

53. Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data

Author

Heneghan, Carl, primary, Ward, Alison, additional, Perera, Rafael, additional, Bankhead, Clare, additional, Fuller, Alice, additional, Stevens, Richard, additional, Bradford, Kairen, additional, Tyndel, Sally, additional, Alonso-Coello, Pablo, additional, Ansell, Jack, additional, Beyth, Rebecca, additional, Bernardo, Artur, additional, Christensen, Thomas Decker, additional, Cromheecke, Manon, additional, Edson, Robert G, additional, Fitzmaurice, David, additional, Gadisseur, Alain PA, additional, Garcia-Alamino, Josep M, additional, Gardiner, Chris, additional, Hasenkam, Michael, additional, Jacobson, Alan, additional, Kaatz, Scott, additional, Kamali, Farhad, additional, Khan, Tayyaba Irfan, additional, Knight, Eve, additional, Körtke, Heinrich, additional, Levi, Marcel, additional, Matchar, David Bruce, additional, Menéndez-Jándula, Bárbara, additional, Rakovac, Ivo, additional, Schaefer, Christian, additional, Siebenhofer, Andrea, additional, Souto, Juan Carlos, additional, Sunderji, Rubina, additional, Gin, Kenneth, additional, Shalansky, Karen, additional, Völler, Heinz, additional, Wagner, Otto, additional, and Zittermann, Armin, additional

Published
2012
Full Text
View/download PDF

57. Reply

Author

Ness, Paul, primary, Fuller, Alice, additional, and King, Karen E., additional

Published
2002
Full Text
View/download PDF

64. Sepsis after platelet transfusions

Author

Ciavarella, David, Braine, Hayden G., Kickler, Thomas S., Ness, Paul M., Dick, James D., Fuller, Alice K., and Morrow, John F.

Subjects
Blood transfusion -- Complications, Bacterial infections -- Causes of
Published
1992

65. Profound thrombocytopenia and survival of hematopoietic stem cell transplant patients without clinically significant bleeding, using prophylactic platelet transfusion triggers of 10 × 109 or 20 × 109 per L.

Author

Nevo, Shoshan, Fuller, Alice K., Zahurak, Marianna L., Hartley, Eric, Borinsky, Mark E., and Vogelsang, Georgia B.

Subjects
*THROMBOCYTOPENIA, *HEMATOPOIETIC stem cells, *BLOOD platelet transfusion, *HEMORRHAGE, *DRUG therapy, *MORTALITY
Abstract

BACKGROUND: A trigger of 10 × 109 per L for prophylactic platelet (PLT) transfusions is generally recommended for stable thrombocytopenic patients who receive chemotherapy, based on studies showing similar incidence, severity, and fatality of bleeding compared with the 20 × 109 per L trigger. The outcome of thrombocytopenic nonbleeding patients has not been well described. This retrospective analysis evaluates thrombocytopenia and survival of 381 hematopoietic stem cell transplant (HSCT) patients without clinically significant bleeding, with 10 × 109 and 20 × 109 per L prophylactic triggers. STUDY DESIGN AND METHODS: A total of 170 patients who received prophylactic PLT transfusions at 20 × 109 per L (1997-1998, SP1) and 211 patients who had prophylaxis at 10 × 109 per L (1999-2001, SP2) were identified as nonbleeding patients. PLT counts and clinical complications were assessed within 100 days from HSCT. RESULTS: PLT counts less than or equal to 10 × 109 per L were found in 69.2 percent of patients in SP2 and 38.3 percent in SP1 (p < 0.001). Profound thrombocytopenia (4+ PLT counts ≤10 × 109/L) was found in 19.0 percent of patients in SP2 and 7.0 percent in SP1 (p = 0.001). Patients with profound thrombocytopenia had significantly increased early mortality (odds ratio [OR], 3.18; 95% confidence interval [CI], 1.25-8.07) and significantly reduced overall survival (hazard ratio [HR], 1.95; 95% CI, 1.28-2.97) compared to patients with 0 to 3 PLT counts less than or equal to 10 × 109 per L. The association of profound thrombocytopenia with early mortality was more notable in SP2. CONCLUSION: The 10 × 109 per L transfusion trigger is associated with significantly greater exposure to low PLT counts. Nonbleeding patients with profound thrombocytopenia were at significantly greater risk of dying compared with nonthrombocytopenic patients. These results suggest that safety of the 10 × 109 per L trigger should be more thoroughly evaluated. [ABSTRACT FROM AUTHOR]

Published
2007
Full Text
View/download PDF

71. ANATOMY AND PHYSIOLOGY OF THE GALLBLADDER IN CHILDREN: A CHOLECYSTOGRAPHIC STUDY

Author

BOYDEN, EDWARD A. and FULLER, ALICE H.

Abstract

The present study consists primarily of a comparison of the evacuation of the gallbladder in children with the emptying of that viscus in young adults, and is a continuation of a preliminary study made several years ago.1 It is, therefore, an attempt to add to the meager knowledge of the physiologic changes which accompany the growth and development of the gastro-intestinal tract in human beings.The methods employed were similar to those by which the norm of the adult organ was established.2 Each gallbladder was visualized by oral administration of tetra-iodophenolphthalein—from 2 to 3 Gm. in grape juice, given in two successive doses the night before roentgenograms were made. The next morning, after preliminary films were made, roentgenograms were immediately made again, and the patient was given a glass of yolks of three eggs stirred in milk. Roentgenograms were then made two, four, eight, twelve, sixteen, twenty, twenty-five,

Published
1934
Full Text
View/download PDF

72. Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer The FACS Randomized Clinical Trial

Author

Primrose, John N., Perera, Rafael, Gray, Alistair, Rose, Peter, Fuller, Alice, Corkhill, Andrea, George, Steve, Mant, David, Primrose, John N., Perera, Rafael, Gray, Alistair, Rose, Peter, Fuller, Alice, Corkhill, Andrea, George, Steve, and Mant, David

Abstract

IMPORTANCE Intensive follow-up after surgery for colorectal cancer is common practice but is based on limited evidence. OBJECTIVE To assess the effect of scheduled blood measurement of carcinoembryonic antigen (CEA) and computed tomography (CT) as follow-up to detect recurrent colorectal cancer treatable with curative intent. DESIGN, SETTING, AND PARTICIPANTS Randomized clinical trial in 39 National Health Service hospitals in the United Kingdom; 1202 eligible participants were recruited between January 2003 and August 2009 who had undergone curative surgery for primary colorectal cancer, including adjuvant treatment if indicated, with no evidence of residual disease on investigation. INTERVENTIONS Participants were randomly assigned to 1 of 4 groups: CEA only (n = 300), CT only (n = 299), CEA+CT (n = 302), or minimum follow-up (n = 301). Blood CEA was measured every 3 months for 2 years, then every 6 months for 3 years; CT scans of the chest, abdomen, and pelvis were performed every 6 months for 2 years, then annually for 3 years; and the minimum follow-up group received follow-up if symptoms occurred. MAIN OUTCOMES AND MEASURES The primary outcome was surgical treatment of recurrence with curative intent; secondary outcomes were mortality (total and colorectal cancer), time to detection of recurrence, and survival after treatment of recurrence with curative intent. RESULTS After a mean 4.4 (SD, 0.8) years of observation, cancer recurrence was detected in 199 participants (16.6%; 95% CI, 14.5%-18.7%) overall; 71 of 1202 participants (5.9%; 95% CI, 4.6%-7.2%) were treated for recurrence with curative intent, with little difference according to Dukes staging (stage A, 5.1% [13/254]; stage B, 6.1% [34/553]; stage C, 6.2% [22/354]). Surgical treatment of recurrence with curative intent was 2.3% (7/301) in the minimum follow-up group, 6.7% (20/300) in the CEA group, 8% (24/299) in the CT group, and 6.6% (20/302) in the CEA+CT group. Compared with minimum follow-up, the

Full Text
View/download PDF

73. Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer The FACS Randomized Clinical Trial

Author

Primrose, John N., Perera, Rafael, Gray, Alistair, Rose, Peter, Fuller, Alice, Corkhill, Andrea, George, Steve, Mant, David, Primrose, John N., Perera, Rafael, Gray, Alistair, Rose, Peter, Fuller, Alice, Corkhill, Andrea, George, Steve, and Mant, David

Abstract

IMPORTANCE Intensive follow-up after surgery for colorectal cancer is common practice but is based on limited evidence. OBJECTIVE To assess the effect of scheduled blood measurement of carcinoembryonic antigen (CEA) and computed tomography (CT) as follow-up to detect recurrent colorectal cancer treatable with curative intent. DESIGN, SETTING, AND PARTICIPANTS Randomized clinical trial in 39 National Health Service hospitals in the United Kingdom; 1202 eligible participants were recruited between January 2003 and August 2009 who had undergone curative surgery for primary colorectal cancer, including adjuvant treatment if indicated, with no evidence of residual disease on investigation. INTERVENTIONS Participants were randomly assigned to 1 of 4 groups: CEA only (n = 300), CT only (n = 299), CEA+CT (n = 302), or minimum follow-up (n = 301). Blood CEA was measured every 3 months for 2 years, then every 6 months for 3 years; CT scans of the chest, abdomen, and pelvis were performed every 6 months for 2 years, then annually for 3 years; and the minimum follow-up group received follow-up if symptoms occurred. MAIN OUTCOMES AND MEASURES The primary outcome was surgical treatment of recurrence with curative intent; secondary outcomes were mortality (total and colorectal cancer), time to detection of recurrence, and survival after treatment of recurrence with curative intent. RESULTS After a mean 4.4 (SD, 0.8) years of observation, cancer recurrence was detected in 199 participants (16.6%; 95% CI, 14.5%-18.7%) overall; 71 of 1202 participants (5.9%; 95% CI, 4.6%-7.2%) were treated for recurrence with curative intent, with little difference according to Dukes staging (stage A, 5.1% [13/254]; stage B, 6.1% [34/553]; stage C, 6.2% [22/354]). Surgical treatment of recurrence with curative intent was 2.3% (7/301) in the minimum follow-up group, 6.7% (20/300) in the CEA group, 8% (24/299) in the CT group, and 6.6% (20/302) in the CEA+CT group. Compared with minimum follow-up, the

Full Text
View/download PDF

74. Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer The FACS Randomized Clinical Trial

Author

Primrose, John N., Perera, Rafael, Gray, Alistair, Rose, Peter, Fuller, Alice, Corkhill, Andrea, George, Steve, Mant, David, Primrose, John N., Perera, Rafael, Gray, Alistair, Rose, Peter, Fuller, Alice, Corkhill, Andrea, George, Steve, and Mant, David

Abstract

IMPORTANCE Intensive follow-up after surgery for colorectal cancer is common practice but is based on limited evidence. OBJECTIVE To assess the effect of scheduled blood measurement of carcinoembryonic antigen (CEA) and computed tomography (CT) as follow-up to detect recurrent colorectal cancer treatable with curative intent. DESIGN, SETTING, AND PARTICIPANTS Randomized clinical trial in 39 National Health Service hospitals in the United Kingdom; 1202 eligible participants were recruited between January 2003 and August 2009 who had undergone curative surgery for primary colorectal cancer, including adjuvant treatment if indicated, with no evidence of residual disease on investigation. INTERVENTIONS Participants were randomly assigned to 1 of 4 groups: CEA only (n = 300), CT only (n = 299), CEA+CT (n = 302), or minimum follow-up (n = 301). Blood CEA was measured every 3 months for 2 years, then every 6 months for 3 years; CT scans of the chest, abdomen, and pelvis were performed every 6 months for 2 years, then annually for 3 years; and the minimum follow-up group received follow-up if symptoms occurred. MAIN OUTCOMES AND MEASURES The primary outcome was surgical treatment of recurrence with curative intent; secondary outcomes were mortality (total and colorectal cancer), time to detection of recurrence, and survival after treatment of recurrence with curative intent. RESULTS After a mean 4.4 (SD, 0.8) years of observation, cancer recurrence was detected in 199 participants (16.6%; 95% CI, 14.5%-18.7%) overall; 71 of 1202 participants (5.9%; 95% CI, 4.6%-7.2%) were treated for recurrence with curative intent, with little difference according to Dukes staging (stage A, 5.1% [13/254]; stage B, 6.1% [34/553]; stage C, 6.2% [22/354]). Surgical treatment of recurrence with curative intent was 2.3% (7/301) in the minimum follow-up group, 6.7% (20/300) in the CEA group, 8% (24/299) in the CT group, and 6.6% (20/302) in the CEA+CT group. Compared with minimum follow-up, the

Full Text
View/download PDF

75. Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer The FACS Randomized Clinical Trial

Author

Primrose, John N., Perera, Rafael, Gray, Alistair, Rose, Peter, Fuller, Alice, Corkhill, Andrea, George, Steve, Mant, David, Primrose, John N., Perera, Rafael, Gray, Alistair, Rose, Peter, Fuller, Alice, Corkhill, Andrea, George, Steve, and Mant, David

Abstract

IMPORTANCE Intensive follow-up after surgery for colorectal cancer is common practice but is based on limited evidence. OBJECTIVE To assess the effect of scheduled blood measurement of carcinoembryonic antigen (CEA) and computed tomography (CT) as follow-up to detect recurrent colorectal cancer treatable with curative intent. DESIGN, SETTING, AND PARTICIPANTS Randomized clinical trial in 39 National Health Service hospitals in the United Kingdom; 1202 eligible participants were recruited between January 2003 and August 2009 who had undergone curative surgery for primary colorectal cancer, including adjuvant treatment if indicated, with no evidence of residual disease on investigation. INTERVENTIONS Participants were randomly assigned to 1 of 4 groups: CEA only (n = 300), CT only (n = 299), CEA+CT (n = 302), or minimum follow-up (n = 301). Blood CEA was measured every 3 months for 2 years, then every 6 months for 3 years; CT scans of the chest, abdomen, and pelvis were performed every 6 months for 2 years, then annually for 3 years; and the minimum follow-up group received follow-up if symptoms occurred. MAIN OUTCOMES AND MEASURES The primary outcome was surgical treatment of recurrence with curative intent; secondary outcomes were mortality (total and colorectal cancer), time to detection of recurrence, and survival after treatment of recurrence with curative intent. RESULTS After a mean 4.4 (SD, 0.8) years of observation, cancer recurrence was detected in 199 participants (16.6%; 95% CI, 14.5%-18.7%) overall; 71 of 1202 participants (5.9%; 95% CI, 4.6%-7.2%) were treated for recurrence with curative intent, with little difference according to Dukes staging (stage A, 5.1% [13/254]; stage B, 6.1% [34/553]; stage C, 6.2% [22/354]). Surgical treatment of recurrence with curative intent was 2.3% (7/301) in the minimum follow-up group, 6.7% (20/300) in the CEA group, 8% (24/299) in the CT group, and 6.6% (20/302) in the CEA+CT group. Compared with minimum follow-up, the

Full Text
View/download PDF

77. A wife manufactured to order

Author

Fuller, Alice W., University of Virginia, Fuller, Alice W., and University of Virginia

Subjects
Man-woman relationships--Fiction
Published
1995

78. Acute bleeding complications in patients after hematopoietic stem cell transplantation with prophylactic platelet transfusion triggers of 10 x 10(9) and 20 x 10(9) per L.

Author

Nevo S, Fuller AK, Hartley E, Borinsky ME, and Vogelsang GB

Subjects
Acute Disease, Adolescent, Adult, Hematopoietic Stem Cell Transplantation methods, Hemorrhage mortality, Humans, Leukemia blood, Leukemia therapy, Logistic Models, Middle Aged, Platelet Count, Platelet Transfusion methods, Retrospective Studies, Survival Rate, Time Factors, Hematopoietic Stem Cell Transplantation adverse effects, Hemorrhage etiology, Platelet Transfusion adverse effects
Abstract

Background: Prophylactic platelet (PLT) transfusions are given as a standard care in patients with hematologic malignancies undergoing hematopoietic stem cell transplantation (HSCT). This retrospective analysis evaluates utilization of blood transfusions, risk of bleeding, and survival in 480 HSCT patients at 10 x 10(9) and 20 x 10(9) per L prophylactic trigger levels., Study Design and Methods: A total of 224 patients received prophylactic PLT transfusions at 20 x 10(9) per L threshold (1997-1998, SP1); 256 patients had prophylaxis at 10 x 10(9) per L (1999-2001, SP2). Bleeding scores were assigned daily., Results: A slight reduction in PLT transfusions per patient in SP2 compared with SP1 was not statistically significant (odds ratio, 0.82; 95% confidence interval, 0.51-1.33; p = 0.416), yet a significantly higher proportion of patients in SP2 had PLT counts less than or equal to 10 x 10(9) per L compared to SP1 (p < 0.001). In patients who bled, however, there was no excess exposure to low PLT counts before bleeding started. A substantial number of patients who bled received PLT transfusions above the goal before bleeding started (82.9% in SP2, 41.5% in SP1) because of medical complications that associated with increased risk of bleeding. Bleeding incidence was similar in both study periods (21.9% in SP1, 16.4% in SP2; p = 0.526). Bleeding was significantly associated with reduced survival in both study periods., Conclusions: Patients who bled were usually placed on a higher threshold before the onset of their major bleeding event and were not exposed to additional risk of bleeding from thrombocytopenia. Similarity in bleeding incidence between study periods appears to associate with adjustments to high-risk conditions and may not reflect consequences of the lower transfusion threshold.

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results